These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 1582520

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Intravenous methylprednisolone pulse therapy for Graves' ophthalmopathy.
    Hiromatsu Y, Tanaka K, Sato M, Kuroki T, Nonaka K, Kojima K, Nishimura H, Nishida H, Kaise N.
    Endocr J; 1993 Feb; 40(1):63-72. PubMed ID: 7951498
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy.
    Hiromatsu Y, Kojima K, Ishisaka N, Tanaka K, Sato M, Nonaka K, Nishimura H, Nishida H.
    Thyroid; 1992 Feb; 2(4):299-305. PubMed ID: 1493371
    [Abstract] [Full Text] [Related]

  • 5. [Management of Graves' ophthalmopathy by using orbital magnetic resonance imaging].
    Hiromatsu Y, Eguchi H, Tani J.
    Nihon Rinsho; 2012 Nov; 70(11):1932-7. PubMed ID: 23214064
    [Abstract] [Full Text] [Related]

  • 6. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy.
    Ohtsuka K, Sato A, Kawaguchi S, Hashimoto M, Suzuki Y.
    Am J Ophthalmol; 2003 Mar; 135(3):285-90. PubMed ID: 12614743
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy.
    Nagayama Y, Izumi M, Kiriyama T, Yokoyama N, Morita S, Kakezono F, Ohtakara S, Morimoto I, Okamoto S, Nagataki S.
    Acta Endocrinol (Copenh); 1987 Dec; 116(4):513-8. PubMed ID: 3321820
    [Abstract] [Full Text] [Related]

  • 14. Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy.
    Higashiyama T, Nishida Y, Morino K, Ugi S, Nishio Y, Maegawa H, Ohji M.
    Jpn J Ophthalmol; 2015 Mar; 59(2):124-30. PubMed ID: 25448468
    [Abstract] [Full Text] [Related]

  • 15. Therapy of Graves' ophthalmopathy with intravenous high-dose steroid followed by orbital irradiation.
    Koshiyama H, Koh T, Fujiwara K, Hayakawa K, Shimbo S, Misaki T.
    Thyroid; 1994 Mar; 4(4):409-13. PubMed ID: 7711503
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Thyroid stimulating antibody in sera of Graves' ophthalmopathy patients as a possible marker for predicting the efficacy of methylprednisolone pulse therapy.
    Mori S, Yoshikawa N, Horimoto M, Yoshimura M, Ogawa Y, Nishikawa M, Inada M.
    Endocr J; 1995 Jun; 42(3):441-8. PubMed ID: 7670573
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [MR relaxation time measurements with and without selective fat suppression (SPIR) in endocrine orbitopathy].
    Pauleit D, Schüller H, Textor J, Leutner C, Keller E, Sommer T, Träber F, Block W, Boldt I, Schild H.
    Rofo; 1997 Dec; 167(6):557-64. PubMed ID: 9465949
    [Abstract] [Full Text] [Related]

  • 20. MR T2 relaxation time for the assessment of retrobulbar inflammation in Graves' ophthalmopathy.
    Utech CI, Khatibnia U, Winter PF, Wulle KG.
    Thyroid; 1995 Jun; 5(3):185-93. PubMed ID: 7580266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.